The SANDPIPER study was a phase III randomized, placebo-controlled trial of taselisib plus fulvestrant compared placebo plus fulvestrant in patients with HR+ PIK3CA mutant, locally advanced, or metastatic AI-resistant breast cancer. This evidence concerns the gene PIK3CA and breast carcinoma.